table of content
1 Introduction to Research & Analysis Reports
1.1 Tumor Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Immunotherapy Overall Market Size
2.1 Global Tumor Immunotherapy Market Size: 2022 VS 2032
2.2 Global Tumor Immunotherapy Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Tumor Immunotherapy Players in Global Market
3.2 Top Global Tumor Immunotherapy Companies Ranked by Revenue
3.3 Global Tumor Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Tumor Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Tumor Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Tumor Immunotherapy Market Size Markets, 2022 & 2032
4.1.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
4.1.3 Engineered T Cell Receptor (TCR) Therapy
4.1.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
4.1.5 Natural Killer (NK) Cell Therapy
4.1.6 Other
4.2 By Type - Global Tumor Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Tumor Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global Tumor Immunotherapy Revenue, 2024-2032
4.2.3 By Type - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Tumor Immunotherapy Market Size, 2022 & 2032
5.1.2 Biopharmaceutical Company
5.1.3 Hospital
5.1.4 Universities And Other Scientific Research Institutions
5.1.5 Other
5.2 By Application - Global Tumor Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Tumor Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global Tumor Immunotherapy Revenue, 2024-2032
5.2.3 By Application - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Tumor Immunotherapy Market Size, 2022 & 2032
6.2 By Region - Global Tumor Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Tumor Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global Tumor Immunotherapy Revenue, 2024-2032
6.2.3 By Region - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Tumor Immunotherapy Revenue, 2018-2032
6.3.2 US Tumor Immunotherapy Market Size, 2018-2032
6.3.3 Canada Tumor Immunotherapy Market Size, 2018-2032
6.3.4 Mexico Tumor Immunotherapy Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Tumor Immunotherapy Revenue, 2018-2032
6.4.2 Germany Tumor Immunotherapy Market Size, 2018-2032
6.4.3 France Tumor Immunotherapy Market Size, 2018-2032
6.4.4 U.K. Tumor Immunotherapy Market Size, 2018-2032
6.4.5 Italy Tumor Immunotherapy Market Size, 2018-2032
6.4.6 Russia Tumor Immunotherapy Market Size, 2018-2032
6.4.7 Nordic Countries Tumor Immunotherapy Market Size, 2018-2032
6.4.8 Benelux Tumor Immunotherapy Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Tumor Immunotherapy Revenue, 2018-2032
6.5.2 China Tumor Immunotherapy Market Size, 2018-2032
6.5.3 Japan Tumor Immunotherapy Market Size, 2018-2032
6.5.4 South Korea Tumor Immunotherapy Market Size, 2018-2032
6.5.5 Southeast Asia Tumor Immunotherapy Market Size, 2018-2032
6.5.6 India Tumor Immunotherapy Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Tumor Immunotherapy Revenue, 2018-2032
6.6.2 Brazil Tumor Immunotherapy Market Size, 2018-2032
6.6.3 Argentina Tumor Immunotherapy Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Tumor Immunotherapy Revenue, 2018-2032
6.7.2 Turkey Tumor Immunotherapy Market Size, 2018-2032
6.7.3 Israel Tumor Immunotherapy Market Size, 2018-2032
6.7.4 Saudi Arabia Tumor Immunotherapy Market Size, 2018-2032
6.7.5 UAE Tumor Immunotherapy Market Size, 2018-2032
7 Tumor Immunotherapy Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Tumor Immunotherapy Major Product Offerings
7.1.4 Roche Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Tumor Immunotherapy Major Product Offerings
7.2.4 Merck Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Tumor Immunotherapy Major Product Offerings
7.3.4 Novartis Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Tumor Immunotherapy Major Product Offerings
7.4.4 Johnson & Johnson Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Summary
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Tumor Immunotherapy Major Product Offerings
7.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 GlaxoSmithKline Key News & Latest Developments
7.6 AbbVie
7.6.1 AbbVie Company Summary
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Tumor Immunotherapy Major Product Offerings
7.6.4 AbbVie Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 AbbVie Key News & Latest Developments
7.7 ELI Lilly
7.7.1 ELI Lilly Company Summary
7.7.2 ELI Lilly Business Overview
7.7.3 ELI Lilly Tumor Immunotherapy Major Product Offerings
7.7.4 ELI Lilly Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 ELI Lilly Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Tumor Immunotherapy Major Product Offerings
7.8.4 Amgen Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Company Summary
7.9.2 AstraZeneca Business Overview
7.9.3 AstraZeneca Tumor Immunotherapy Major Product Offerings
7.9.4 AstraZeneca Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 AstraZeneca Key News & Latest Developments
7.10 Bristol-Mysers Squibb
7.10.1 Bristol-Mysers Squibb Company Summary
7.10.2 Bristol-Mysers Squibb Business Overview
7.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Major Product Offerings
7.10.4 Bristol-Mysers Squibb Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.10.5 Bristol-Mysers Squibb Key News & Latest Developments
7.11 Kite Pharma
7.11.1 Kite Pharma Company Summary
7.11.2 Kite Pharma Business Overview
7.11.3 Kite Pharma Tumor Immunotherapy Major Product Offerings
7.11.4 Kite Pharma Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.11.5 Kite Pharma Key News & Latest Developments
7.12 Adaptimmune
7.12.1 Adaptimmune Company Summary
7.12.2 Adaptimmune Business Overview
7.12.3 Adaptimmune Tumor Immunotherapy Major Product Offerings
7.12.4 Adaptimmune Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.12.5 Adaptimmune Key News & Latest Developments
7.13 Altor Bioscience Corporation
7.13.1 Altor Bioscience Corporation Company Summary
7.13.2 Altor Bioscience Corporation Business Overview
7.13.3 Altor Bioscience Corporation Tumor Immunotherapy Major Product Offerings
7.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.13.5 Altor Bioscience Corporation Key News & Latest Developments
7.14 Cellectis
7.14.1 Cellectis Company Summary
7.14.2 Cellectis Business Overview
7.14.3 Cellectis Tumor Immunotherapy Major Product Offerings
7.14.4 Cellectis Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.14.5 Cellectis Key News & Latest Developments
7.15 Juno Therapeutics
7.15.1 Juno Therapeutics Company Summary
7.15.2 Juno Therapeutics Business Overview
7.15.3 Juno Therapeutics Tumor Immunotherapy Major Product Offerings
7.15.4 Juno Therapeutics Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.15.5 Juno Therapeutics Key News & Latest Developments
7.16 Takara Bio
7.16.1 Takara Bio Company Summary
7.16.2 Takara Bio Business Overview
7.16.3 Takara Bio Tumor Immunotherapy Major Product Offerings
7.16.4 Takara Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.16.5 Takara Bio Key News & Latest Developments
7.17 Unum Therapeutics
7.17.1 Unum Therapeutics Company Summary
7.17.2 Unum Therapeutics Business Overview
7.17.3 Unum Therapeutics Tumor Immunotherapy Major Product Offerings
7.17.4 Unum Therapeutics Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.17.5 Unum Therapeutics Key News & Latest Developments
7.18 Sunway
7.18.1 Sunway Company Summary
7.18.2 Sunway Business Overview
7.18.3 Sunway Tumor Immunotherapy Major Product Offerings
7.18.4 Sunway Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.18.5 Sunway Key News & Latest Developments
7.19 Junshi Bio
7.19.1 Junshi Bio Company Summary
7.19.2 Junshi Bio Business Overview
7.19.3 Junshi Bio Tumor Immunotherapy Major Product Offerings
7.19.4 Junshi Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.19.5 Junshi Bio Key News & Latest Developments
7.20 Cinda Bio
7.20.1 Cinda Bio Company Summary
7.20.2 Cinda Bio Business Overview
7.20.3 Cinda Bio Tumor Immunotherapy Major Product Offerings
7.20.4 Cinda Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.20.5 Cinda Bio Key News & Latest Developments
7.21 BeiGene
7.21.1 BeiGene Company Summary
7.21.2 BeiGene Business Overview
7.21.3 BeiGene Tumor Immunotherapy Major Product Offerings
7.21.4 BeiGene Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.21.5 BeiGene Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
